Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
TRK-001 + tacrolimus
- Development stage
- Phase 2
- Lead developer
- Tract Therapeutics
- Modality
- Small Molecules
- Administration
- Oral, Intravenous, Topical
01
Overview
TRK-001 + tacrolimus is a combination drug consisting of TRK-001 and tacrolimus. Tacrolimus is a small-molecule immunosuppressant, specifically a calcineurin inhibitor, used primarily to prevent organ transplant rejection. It inhibits T-cell activation by binding to FKBP-12, forming a complex that inhibits calcineurin phosphatase activity, resulting in reduced transcription of interleukin-2 and other cytokines and blocking the progression of T cells from the G0 to G1 phase[3][4][1]. No definitive information is available in the provided data regarding TRK-001’s mechanism, structure, or clinical indications when used in combination with tacrolimus. As a result, the description is limited to the known properties of tacrolimus and the structure of the combination.
- Brand names
- AstagrafModigrafTacforius
- Other names
- FK-506FK506FK 506fujimycintacroTacrolimus anhydrousK506K-506K 506
02
Targets
CN (Calcineurin)FKBP1A
Beyond the preview
Go deeper on TRK-001 + tacrolimus.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on TRK-001 + tacrolimus.